Oncotarget

Reviews:

Advances in epigenetic glioblastoma therapy

Dong Hoon Lee, Hyun-Wook Ryu, Hye-Rim Won and So Hee Kwon _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:18577-18589. https://doi.org/10.18632/oncotarget.14612

Metrics: PDF 1722 views  |   HTML 2026 views  |   ?  


Abstract

Dong Hoon Lee1,2, Hyun-Wook Ryu1, Hye-Rim Won1 and So Hee Kwon1

1 College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Republic of Korea

2 Department of Integrated OMICS for Biomedical Science, Yonsei University, Seoul, Republic of Korea

Correspondence to:

So Hee Kwon, email:

Keywords: histone deacetylase; histone deacetylase inhibitor; glioblastoma; epigenetic therapy

Received: August 16, 2016 Accepted: January 04, 2017 Published: January 12, 2017

Abstract

Glioblastoma multiforme (GBM) is the most lethal primary brain tumor in adults despite contemporary gold-standard first-line treatment strategies. This type of tumor recurs in virtually all patients and no commonly accepted standard treatment exists for the recurrent disease. Therefore, advances in all scientific and clinical aspects of GBM are urgently needed. Epigenetic mechanisms are one of the major factors contributing to the pathogenesis of cancers, including glioblastoma. Epigenetic modulators that regulate gene expression by altering the epigenome and non-histone proteins are being exploited as therapeutic drug targets. Over the last decade, numerous preclinical and clinical studies on histone deacetylase (HDAC) inhibitors have shown promising results in various cancers. This article provides an overview of the anticancer mechanisms of HDAC inhibitors and the role of HDAC isoforms in GBM. We also summarize current knowledge on HDAC inhibitors on the basis of preclinical studies and emerging clinical data.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14612